Navigation Links
Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
Date:1/24/2013

from similarly titled measures used by other companies.  Therefore, our non-GAAP financial measures may not be comparable to those used by other companies.  We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.

We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes and incentive compensation for senior management because we believe such measures are one important indicator of the strength and the operating performance of our business.  Analysts and investors frequently ask us for this information.  We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss during the three months ended December 31, 2012 and 2011 was approximately $135,000 and $570,000, respectively.  Our non-GAAP operating loss during the nine months ended December 31, 2012 and 2011 was approximately $858,000 and $2.3 million, respectively.  The decrease in non-GAAP operating loss for the three months ended December 31, 2012 over the corresponding period a year ago is attributed to the increase in net sales and gross profit percent and the decrease in operating spending.  The decrease in non-GAAP operating loss for the nine months ended December 31, 2012 over the corresponding period a year ago is attributed to the increase in net sales and gross profit percent, which more than offset the increase in operating spending.

 Expense AdjustmentsThree-Months EndedGAAPShare-based  ExpenseDepreciationAmortization of IntangiblesNon-GAAPDecember 31, 2012Gross Profit

$4,856,000

$8,000

$8,000$4,872,000% of net sales

86.9%87.2%Operating Exp
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference
2. Uroplasty To Participate In Two Upcoming Investor Conferences
3. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
4. Uroplasty To Participate In Two Upcoming Conferences
5. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
6. Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
7. Uroplasty To Present At The JMP Securities Healthcare Conference
8. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
9. Uroplasty Announces Product Development and New Clinical Trial Initiatives
10. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
11. Cepheid Reports Fourth Quarter And Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013  Echo Pharma Acquisition Limited ("Royalty ... Irish Takeover Rules (the "Announcement"), a firm intention to ... ELN ) to $12.50 per share in cash.  ... not conditional on due diligence.  The $1.00 per share ... reserved the right to waive down the Acceptance Threshold ...
(Date:5/20/2013)...  Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company ... technology to deter prescription drug abuse today announced ... Soscia , has been chosen as a ... Health-Care Heroes Awards. The awards are presented annually ... individuals and organizations demonstrating excellence and deserving recognition ...
(Date:5/20/2013)... -- Rhythm announced today the presentation of results from a ... symptoms among diabetic patients in the U.S. than previously ... with both type 1 and type 2 diabetes, but ... more common type 2 disease. ... of Medicine at Harvard Medical School and Director of ...
Breaking Medicine Technology:Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4
... This May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic ... European industry experts at Pharma IQ,s to discuss FDA ... Over the last two years, the regulations have been ... there has been some confusion within the industry as ...
... 2011 Morphotek®, Inc., a subsidiary of Eisai ... assets relating to a proprietary tumor targeting platform ... payment and future development milestones. TMI, a biotechnology ... the tumor-targeting peptide (TTP) platform capable of delivering ...
Cached Medicine Technology:FDA to Address Industry Questions About Biosimilar Regulations at the Pharma's IQ Immunogenicity Event 2Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc. 2Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc. 3
(Date:5/20/2013)... 20, 2013 ... be holding a lupus support ... June 10th. , Meeting Details: ... p.m. – 8 p.m., Location: ... Sparrow Hospital),                  1200 East ...
(Date:5/20/2013)... Lake City, UT (PRWEB) May 20, 2013 ... named one of Select Health’s Select 25 winners ... receive $2500 from Select Health. Know Greater Heroes is a ... local elementary schools to teach children how to eat right, ... student athletes participate in the Know Greater Heroes program each ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Osborn’s ... successor to Anne G. Osborn’s 1993 award winning book ... of the all-time bestselling neuroradiology texts. , In ... special touch to make complex topics visually appealing and ... of brain imaging together with spectacular pathology examples, relevant ...
(Date:5/20/2013)... May 20, 2013 Nearly 20 percent of ... U.S. are refused for transplant due to factors ranging ... filtering units to the organ going too long without ... discarded, these organs could be "recycled" to help solve ... Wake Forest Baptist Medical Center and colleagues, reporting in ...
(Date:5/20/2013)... 2013 What:    USO Care ... President, USO and CEO , ... Initiatives and Partners, Sesame Street , ... from:,              • ... • U.S. House of Representatives ...
Breaking Medicine News(10 mins):Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3Health News:Osborn’s Brain from Amirsys Publishing Receives Doody’s Top Honors 2Health News:Study suggests new source of kidneys for transplant 2Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 2Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 3Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 4
... By Amanda Gardner HealthDay Reporter , TUESDAY, ... belly fat of 10 heart attack patients managed to improve ... is the first time this type of therapy has been ... Tuesday at the American Heart Association,s annual meeting in Chicago. ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Nov. ... advisers were weighing Tuesday whether to recommend the first ... the autoimmune disease lupus. The drug, belimumab (Benlysta), ... treat patients who suffer from systemic lupus erythematosus. ...
... study from the Swedish medical university Karolinska Institutet shows ... aneurysm. These drugs, which block cysteinyl-leukotrienes, could reduce the ... of the aortic wall, and thus the risk of ... the need for complicated and risky surgery. The results ...
... MONDAY, Nov. 15 (HealthDay News) -- It rarely happens, ... and sponges are left inside children undergoing surgery, according to ... mishaps were not more likely to die, but the errors ... long and cost more than double that of the average ...
... The risk of radiation-induced breast cancer from mammography screening ... saved, according to a new study appearing online and in ... "Recently, there have been reports in the press focusing on ... periodic screening," said the study,s lead author, Martin J. Yaffe, ...
... factor 7 (rFVIIa) a drug used to treat ... not recommended because of the potential for adverse events, ... Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100408.pdf. Recombinant activated factor ... of bleeding in hemophilia patients. It is also used ...
Cached Medicine News:Health News:Study Hints at Stem Cells From Belly Fat as Treatment for Heart Attack 2Health News:Study Hints at Stem Cells From Belly Fat as Treatment for Heart Attack 3Health News:FDA Advisers Consider New Lupus Drug 2Health News:Aortic aneurysm treatable with asthma drugs 2Health News:Sponges, Surgical Tools Sometimes Left in Kids After Operation 2Health News:Sponges, Surgical Tools Sometimes Left in Kids After Operation 3Health News:Radiation fears should not deter women from mammography screening 2Health News:Hemostatic drug less effective than originally predicted 2
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Inquire...
The latest VALENTINO eyewear collection is a refined expression of sophisticated luxury,balancing ultimate feminine, chic styles against understated, minimalist mens models....
The Claiborne brand provides the perfect look for the man who wants to be comfortable and relaxed, yet look appropriate for each occasion....
Medicine Products: